Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome

Bibliography

• ABRAMS P, CARDOZO L, MAGNUS F et al.: The standardization οf terminology οf lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol. Urodyn. (2002) 21:167-178.
   PubMed Web of Science ®Google Scholar
• HU TW, WAGNER TH, BENTKOVER JD, LEBLANC K, ZHOU SZ, HUNT T: Costs of urinary incontinence and overative bladder in the United States: a comparative study. Urology (2004) 63:461-465.
   PubMed Web of Science ®Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20:327-336.
   PubMed Web of Science ®Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFFS J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br. J. Urol. Int. (2001) 87:760-766.
   Google Scholar
• KELLEHER CJ: Economic and social impact of OAB. Eur. Urol. Suppl. (2002) 1:11-16.
   Web of Science ®Google Scholar
• CHIAFFARINO F, PARAZZINI F, LAVEZZARI M, GIAMBANCO V, GRUPPO INTERDISCIPLINARE DI STUDIO INCONTINENZA URINARIA (GISIU): Impact of urinary incontinence and overactive bladder on quality of life. Eur. Urol. (2003) 43(5):535-538.
   PubMed Web of Science ®Google Scholar
• LIBERMAN JN, HUNT TL, STEWART WF et al.: Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology (2001) 57(6):1044-50.
   PubMed Web of Science ®Google Scholar
• RICCI JA, BAGGISH JS, HUNT TL et al.: Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin. Ther. (2001) 23(8):1245-1259.
   PubMed Web of Science ®Google Scholar
• BOSCH RJLH: The evolving role of the specialist in the diagnosis and management of the patient with OAB. Eur. Urol. Suppl. (2002) 1:17-22.
   Google Scholar
• ANDERSSON KE: Antimuscarinics for treatment of overactive bladder. Lancet Neurol. (2004) 3:46-53.
   PubMed Web of Science ®Google Scholar
• DE GROAT WC, YOSHIMURA N: Pharmacology of the lower urinary tract. Ann. Rev. Pharmacol. Toxicol. (2001) 41:691-721.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA T, NOZAKI K, FUJITA O, NOSE H, INOUE M, KUMON H: Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity. J. Urol. (2004) 172:596-600.
   PubMedGoogle Scholar
• DE LAET K, DE WACHTER S, WYNDAELE JJ: Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol. Urodyn. (2005) [Epub ahead of print].
   PubMedGoogle Scholar
• WEFER J, TRUSS MC, JONAS U: Tolterodine: an overview. World J. Urol. (2001) 19(5):312-318.
   PubMedGoogle Scholar
• ROBINSON D, CARDOZO L: The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin. Investig. Drugs. (2004) 13(10):1339-48.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR: Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin. Investig. Drugs. (2004) 13(11):1493-1500.
   PubMed Web of Science ®Google Scholar
• HOFNER K, OELKE M, MACHTENS S, GRUNEWALD V: Trospium chloride – an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J. Urol. (2001) 19(5):336-343.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, CHAPPLE CR: Oxybutynin and the overactive bladder. World J. Urol. (2001) 19(5):319-312.
   PubMed Web of Science ®Google Scholar
• DE WACHTER S, WYNDAELE JJ: Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J. Urol. (2003) 169:1892-1895.
   PubMed Web of Science ®Google Scholar
• MADERSBACHER H, MURTZ G: Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J. Urol. (2001) 19(5):324-335.
   PubMed Web of Science ®Google Scholar
• HERBISON P, HAY-SMITH J, ELLIS G, MOORE K: Effectiveness of antimuscarinic drugs compared with placepo in the treatment of overactive bladder: systematic review. Br. Med. J. (2003) 326:841-814.
   PubMed Web of Science ®Google Scholar
• CHAPPLE C, KHULLAR V, GABRIEL Z, DOOLEY JA: The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol. (2005) 48:5-26.
   PubMed Web of Science ®Google Scholar
• MILLARD R, TUTTLE J, MOORE K et al.: Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J. Urol. (1999) 161(5):1551-1555.
   PubMed Web of Science ®Google Scholar
• YAKER Y, GAO KL, FITTON A: Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs Ageing (1995) 6:243-262.
   PubMedGoogle Scholar
• ABRAMS P, FREEMAN R, ANDERTRÖM C, MATTIASSON A: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. (1998) 81:801-810.
   PubMedGoogle Scholar
• GIANNITSAS K, PERIMENIS P, ATHANASOPOULOS A, GYFTOPOULOS K, NIKIFORIDIS G, BARBALIAS G: Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur. Urol. (2004) 46(6):776-782.
   PubMedGoogle Scholar
• ABRAMS P, SWIFT S: Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur. Urol. (2005) 48(3):483-487.
   PubMed Web of Science ®Google Scholar
• MADERSBACHER H, HALASKA M, VOIGT R, ALLOUSSI S, HOFNER K: A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Br. J. Urol. Int. (1999) 84(6):646-651.
   Google Scholar
• JUNEMANN KP, HALASKA M, RITTSTEIN T et al.: Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur. Urol. (2005) 48(3):478-482.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, MARTINEZ-GARCIA R, SELVAGGI L et al.: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol. (2005) 48(3):464-470.
   PubMed Web of Science ®Google Scholar
• HU TW, WAGNER TH, BENTKOVER JD et al.: Estimated economic costs of overactive bladder in the United States. Urology (2003) 61:1123-1128.
   PubMed Web of Science ®Google Scholar
• DARKOW T, FONTES CL, WILLIAMSON TE: Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy (2005) 25:511-519.
   PubMed Web of Science ®Google Scholar
• WU EQ, BIRNBAUM H, MARYNCHENKO M, MAREVA M, WILLIAMSON T, MALLET D: Employees with overactive bladder: work loss burden. J. Occup. Environ. Med. (2005) 47:439-446.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE FMJ, HEESAKKERS JPFA: Clinical and socioeconomic relevance of overactive bladder. Urology (2004) 63:42-44.
   PubMedGoogle Scholar
• DRUMMOND MF, O’BRIEN B, STODDARD GL, TORRANCE GW: Methods for economic evaluation of health care programmes, 2nd edn. Oxford University Press, New York, US (1997).
   Google Scholar
• HU TW, WAGNER TH et al.: Economics of incontinence In: Incontinence. Second International Consultation on Incontinence, 2nd edn. Abrams P, Khoury S, Wein A (Eds). Health Publications, Plymouth, UK (2002):965-983.
   Google Scholar
• MASSON JM: Cost–per QALY league tables: their roles in pharmaeconomics analysis. Pharmacoeconomics (1994) 5:472-481.
   PubMedGoogle Scholar
• KOBELT G, JONSSON L, MATTIASSON A: Cost-effectiveness of new treatments for overactive bladder: the example of tolderodine, a new muscarinic agent: a Markov model. Neurourol. Urodyn. (1998) 17:599-611.
   PubMed Web of Science ®Google Scholar
• JOHANNSSON M, O’CONOR RM, KOBELT-NGUYEN G, MATTIASSON A: Willingness to pay for reduced incontinence symptoms. Br. J. Urol. (1997) 80:557-562.
   PubMedGoogle Scholar
• TEMML C, HEIDLER S, PONHOLZER A, MADERSBACHER S: Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur. Urol. (2005) 48:622-627.
   PubMed Web of Science ®Google Scholar
• HU TW, WAGNER TH: Health-related consequences of overactive bladder: an economic perspective. Br. J. Urol. Int. Suppl. (2005) 96(Suppl. 1):43-45.
   Google Scholar
• ATHANASOPOULOS A, GYFTOPOULOS K, GIANNITSAS K, FISFIS J, PERIMENIS P, BARBALIAS G: Combination treatment with an alpha-blocker plus an antimuscarinic for bladder outlet obstruction: a prospective, randomized, controlled study. J. Urol. (2003) 169(6):2253-2256.
   PubMed Web of Science ®Google Scholar
• LEE JY, KIM HW, LEE SJ, KOH JS, SUH HJ, CHANCELLOR M: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and overactive bladder. Br. J. Urol. Int. (2004) 94:817-820.
   Google Scholar
• ANDERSSON KE, APPELL R, AWAD S et al.: Pharmacological treatment of urinary incontinence. In Incontinence. Second International Consultation on Incontinence, 2nd edn. Abrams P, Khoury S, Wein A (Eds). Health Publications, Plymouth, UK (2002).
   Google Scholar
• WALLACE SA, ROE B, WILLIAMS K, PALMER M: Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev. (2004) 1:CD001308.
   PubMedGoogle Scholar
• ARIKIAN SR, CASCIANO J, DOYLE JJ, TARRIDE JE, CASCIANO RN: A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag. Care Interface (2000) 13(2):88-94.
   PubMedGoogle Scholar
• HUGHES DA, DUBOIS D: Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics (2004) 22(16):1047-1059.
   PubMed Web of Science ®Google Scholar
• GETSIOS D, CARO JJ, ISHAK KJ, EL-HADI W, PAYNE K: Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin. Ther. (2004) 26(3):431-438.
   PubMed Web of Science ®Google Scholar